Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates Oncotelic's proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
The platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. Oncotelic also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, its clinical-stage intravenous everolimus program currently in a Phase 1b study. For more details, view the full press release at https://ibn.fm/upnBW.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics.
The PDAOAI platform is Oncotelic's proprietary AI system for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and ongoing joint development work with TechForce Robotics, Oncotelic's strategic robotics and automation partner. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications. More information is available at https://www.techforcerobotics.com.
The launch of this AI-powered platform represents a significant step in integrating artificial intelligence with pharmaceutical manufacturing, potentially improving efficiency, compliance, and quality control in drug production. The implications for the industry include reduced manual errors, streamlined regulatory adherence, and faster time-to-market for therapies. Oncotelic's CEO, Dr. Vuong Trieu, has emphasized the potential of AI to revolutionize manufacturing, and this platform could set a new standard for GMP operations.
The announcement at BIO 2026, a major industry event, underscores Oncotelic's commitment to innovation and its strategic focus on leveraging technology to address challenges in pharmaceutical manufacturing. The collaboration with TechForce Robotics further strengthens the platform's capabilities, combining AI with advanced robotics to create a comprehensive automation solution. As the pharmaceutical industry increasingly adopts digital and AI technologies, Oncotelic's platform may offer a competitive edge for companies seeking to modernize their manufacturing processes.
